PeptideStack
5.2kquestions
20kanswers
220users

Which single measurement would I keep if I could only have one?

Asked 12 Mar 2026Modified 2 months agoViewed 7.7k times
11

I am comparing a supplier certificate against an independent result on the same lot.

The failure mode I am trying to avoid is making this decision emotionally.

I have twelve months in view and I would like the plan to survive that long.

How would you structure this, and what thresholds would you set in advance?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
shareeditfollowflag
SL
askedsecond_lot9.4k1412 Mar 2026
6Add the gradient and the column if you have them — half the answer depends on those. – sinead_gaffney 5 months ago
5Same question came up on a different supplier and the answer was entirely about the method. – ines_brandt 3 months ago
add a comment

5 Answers

Sorted by votes
29

The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
JW
answeredj_wierzbicki69k1487 Apr 2026
5The system-suitability data is the part that tells you whether to believe the rest. – Dr_Ravi_Selvarajah 8 months ago
4Adding a vote because this deserves more of them. – dana_wexler 6 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
19

Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

edited 23 Apr 2026 by kwn_analytical — added the placebo-arm figures

shareimprove this answerflag
KA
answeredkwn_analytical147k35818 Apr 2026
14

A certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

The underlying point is that testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
P9
answeredplate_count_9k78k24815 Mar 2026
11

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
DF
answeredDr_Colm_Fitzhenry69k24727 Mar 2026
Which wavelength was the purity integrated at? It changes the number more than people think. – h_villanueva 35 days ago
add a comment
9

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

edited 22 May 2026 by mz_4113 — added the method parameters

shareimprove this answerflag
M4
answeredmz_4113101k35821 May 2026
6Small correction: the limit of quantitation, not the limit of detection, is the relevant one there. – ekaterina_volk 4 months ago
5Two of us submitted the same lot to different laboratories and got results a tenth apart. – j_wierzbicki 2 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.